PDA 002

Drug Profile

PDA 002

Alternative Names: PDA-002; PDAC cells; Placental-derived adherent cells intramuscular

Latest Information Update: 21 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Celgene Corporation
  • Class Antiulcers; Skin disorder therapies; Stem cell therapies; Vascular disorder therapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Diabetic foot ulcer; Diabetic neuropathies; Peripheral arterial disorders

Most Recent Events

  • 30 Oct 2017 Celgene completes a phase II trial in Diabetic peripheral neuropathy in USA (NCT02552277)
  • 01 Oct 2016 Celgene completes a phase I trial in Peripheral arterial disorders and Diabetic foot ulcer in USA (IM) (NCT01859117)
  • 20 Apr 2016 Celgene Corporation withdraws a phase II trial in Peripheral arterial disorders and Diabetic foot ulcers prior to enrolment in USA (IM) (NCT02460081)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top